Previous 10 | Next 10 |
2023-06-12 11:59:19 ET Summary Supernus Pharmaceuticals faces declining revenues from its long-time top seller Trokendi XR due to generic competition. Despite Trokendi's struggles, Supernus reported a slim increase in aggregate quarterly revenues, with stagnant revenue guidance fo...
2023-06-10 07:40:00 ET Supernus Pharmaceuticals ' (NASDAQ: SUPN) stock price is up 24% over the last 12 months, suggesting investors are still keen on buying it despite its high valuation and some stiff pressure it's getting on its revenue. What could be driving stock traders to bid...
2023-05-09 21:43:08 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, IR Jack Khattar - CEO Tim Dec - CFO Conference Call Participants Andrew Tsai - Jeff...
2023-05-09 16:20:35 ET Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q1 GAAP EPS of $0.29 beats by $0.55 . Revenue of $153.8M (+0.8% Y/Y) beats by $14.78M . FY23 Total revenues to be $580M - $620M, vs. $599.79M consensus. For further details se...
First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 GOCOVRI ® net product sales of $26.0 million, compared to $22...
ROCKVILLE, Md., May 02, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
ROCKVILLE, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial...
2023-04-04 03:44:22 ET Biopharmaceutical company, Supernus Pharmaceuticals ( NASDAQ: SUPN ) has paid out the total principal amount due of $402.5M under its 0.625% convertible senior notes due 2023. This is in addition to payment of the remaining outstanding interest due o...
ROCKVILLE, Md., April 03, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that it has paid the total principal amount ...
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the Supernus Pharmaceuticals management...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...